MCL1 and lung carcinoma: Although treatment with CFZ or CPPD did not significantly modulate Bcl-2 levels in the H1993 or SHP77 cells (Additional file 1: Figure S2), future studies should investigate the combined activity of CFZ with Bcl-2 and/or Mcl-1 inhibitors in lung cancer.